QN-04

QN-04 is an inhaled drug candidate being developed by Qnovia (formerly Respira Technologies) for the treatment of depression and anxiety. The product utilizes Qnovia's proprietary RespiRx platform, which is an ultrasonic nebulization technology designed to deliver medications directly to the lungs for rapid systemic absorption. This delivery modality aims to provide a faster onset of action compared to traditional oral therapies, which is particularly relevant for neurological and psychiatric indications. As of late 2024, QN-04 is in the formulation and delivery scoping stage, focusing on optimizing the drug's chemical formulation and device requirements. The specific active pharmaceutical ingredient and its molecular mechanism of action have not yet been publicly disclosed.